MX348933B - Composiciones, formas de dosificacion y coadministracion de un compuesto agonista opioide y un compuesto analgesico. - Google Patents

Composiciones, formas de dosificacion y coadministracion de un compuesto agonista opioide y un compuesto analgesico.

Info

Publication number
MX348933B
MX348933B MX2014005571A MX2014005571A MX348933B MX 348933 B MX348933 B MX 348933B MX 2014005571 A MX2014005571 A MX 2014005571A MX 2014005571 A MX2014005571 A MX 2014005571A MX 348933 B MX348933 B MX 348933B
Authority
MX
Mexico
Prior art keywords
compound
opioid agonist
analgesic
dosage forms
compositions
Prior art date
Application number
MX2014005571A
Other languages
English (en)
Spanish (es)
Other versions
MX2014005571A (es
Inventor
Timothy A Riley
Hema Gursahani
Juergen W Pfeiffer
Original Assignee
Nektar Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nektar Therapeutics filed Critical Nektar Therapeutics
Publication of MX2014005571A publication Critical patent/MX2014005571A/es
Publication of MX348933B publication Critical patent/MX348933B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4468Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/74Synthetic polymeric materials
    • A61K31/745Polymers of hydrocarbons
    • A61K31/75Polymers of hydrocarbons of ethene
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/74Synthetic polymeric materials
    • A61K31/785Polymers containing nitrogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/405Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2014005571A 2011-11-07 2012-11-06 Composiciones, formas de dosificacion y coadministracion de un compuesto agonista opioide y un compuesto analgesico. MX348933B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161556693P 2011-11-07 2011-11-07
PCT/US2012/063725 WO2013070617A1 (en) 2011-11-07 2012-11-06 Compositions, dosage forms, and coadministration of an opioid agonist compound and an analgesic compound

Publications (2)

Publication Number Publication Date
MX2014005571A MX2014005571A (es) 2014-07-10
MX348933B true MX348933B (es) 2017-07-03

Family

ID=47297432

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014005571A MX348933B (es) 2011-11-07 2012-11-06 Composiciones, formas de dosificacion y coadministracion de un compuesto agonista opioide y un compuesto analgesico.

Country Status (9)

Country Link
US (2) US9457024B2 (enExample)
EP (1) EP2776046A1 (enExample)
JP (2) JP6593993B2 (enExample)
KR (1) KR102016305B1 (enExample)
CN (1) CN103906522B (enExample)
AU (1) AU2012336030B2 (enExample)
CA (1) CA2854512A1 (enExample)
MX (1) MX348933B (enExample)
WO (1) WO2013070617A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10512644B2 (en) * 2007-03-12 2019-12-24 Inheris Pharmaceuticals, Inc. Oligomer-opioid agonist conjugates
AU2012336030B2 (en) 2011-11-07 2017-09-14 Nektar Therapeutics Compositions, dosage forms, and coadministration of an opioid agonist compound and an analgesic compound
US10525054B2 (en) 2011-11-07 2020-01-07 Inheris Biopharma, Inc. Compositions, dosage forms, and co-administration of an opioid agonist compound and an analgesic compound
CA3042642A1 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
EP3074379B1 (en) * 2013-11-27 2019-06-26 Nektar Therapeutics (India) Pvt. Ltd. Opioid agonists and uses thereof
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
EP3169315B1 (en) 2014-07-17 2020-06-24 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
WO2016064873A1 (en) 2014-10-20 2016-04-28 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
CN105111136B (zh) * 2015-09-16 2017-07-04 上海皓伯化工科技有限公司 一种制备3‑甲基‑1‑苯乙基哌啶‑4‑酮或1‑苯乙基哌啶‑4‑酮的方法
CN107033154B (zh) * 2016-02-02 2020-02-04 上海瀚迈生物医药科技有限公司 阿片受体拮抗剂缀合物及其应用
CN117003693A (zh) * 2022-05-05 2023-11-07 四川大学华西医院 一类哌啶衍生物及其制备方法和用途

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2628962A (en) 1949-10-20 1953-02-17 Mallinckrodt Chemical Works Method for preparing dihydrocodeinone, dihydromorphinone, and codeinone
US2654756A (en) 1949-10-20 1953-10-06 Mallinckrodt Chemical Works Process of preparing codeinone, dihydrocodeinone, and dihydromorphinone
US2649454A (en) 1951-08-20 1953-08-18 Univ California Method for preparing dihydromorphinone, dihydrocodeinone, and dihydropseudocodeinone
US2806033A (en) 1955-08-03 1957-09-10 Lewenstein Morphine derivative
GB971700A (en) * 1961-02-02 1964-09-30 Boots Pure Drug Co Ltd Anti-Inflammatory Agents
AU661723B2 (en) * 1991-10-30 1995-08-03 Mcneilab, Inc. Composition comprising a tramadol material and a non-steroidal anti-inflammatory drug
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
US5840731A (en) * 1995-08-02 1998-11-24 Virginia Commonwealth University Pain-alleviating drug composition and method for alleviating pain
US6835802B2 (en) 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
DK2939696T3 (en) * 2001-10-18 2016-05-23 Nektar Therapeutics Polymer Conjugates of Opioid Antagonists
US7375106B2 (en) 2002-05-16 2008-05-20 N.V. Organon Synergistic combination of an opioid analgesic and a NSAID
DK1694363T3 (en) 2003-12-16 2014-03-24 Nektar Therapeutics Monodisperse PEGylated Naloxole Compositions
CN101410095B (zh) 2006-03-06 2015-07-01 波曾公司 施用组合药物的剂型
EP2019586A4 (en) 2006-05-03 2009-09-02 Proethic Pharmaceuticals Inc MEDICATION OF ACUTE PAIN BASED ON FAST DICLOFENAC OPIOID COMBINATIONS
JP2010509227A (ja) * 2006-11-07 2010-03-25 ネクター セラピューティックス エイエル,コーポレイション オピオイド作動薬およびオピオイド拮抗薬の用量形態および同時投与
EP2134371B1 (en) * 2007-03-12 2015-01-14 Nektar Therapeutics Oligomer-opioid agonist conjugates
US8173666B2 (en) 2007-03-12 2012-05-08 Nektar Therapeutics Oligomer-opioid agonist conjugates
EP2022778A1 (en) * 2007-08-07 2009-02-11 Laboratorios del Dr. Esteve S.A. A crystalline form of (R,R)-tramadol-(S)-naproxene salt
AU2009292631A1 (en) 2008-09-16 2010-03-25 Nektar Therapeutics Pegylated opioids with low potential for abuse
AU2009332963B2 (en) * 2008-12-31 2015-02-05 Upsher-Smith Laboratories, Llc Opioid-containing oral pharmaceutical compositions and methods
CA2768392C (en) * 2009-07-21 2018-04-17 Nektar Therapeutics Oligomer-opioid agonist conjugates
SG10201406930UA (en) 2009-07-27 2014-11-27 Nocicepta Llc Methods For Treatment Of Pain
US8202525B2 (en) * 2009-12-22 2012-06-19 Pondera Biotechnologies, LLC Methods and compositions for treating distress dysfunction and enhancing safety and efficacy of specific medications
US20130023553A1 (en) 2010-01-12 2013-01-24 Nektar Therapeutics Pegylated opioids with low potential for abuse and side effects
AU2012336030B2 (en) 2011-11-07 2017-09-14 Nektar Therapeutics Compositions, dosage forms, and coadministration of an opioid agonist compound and an analgesic compound

Also Published As

Publication number Publication date
WO2013070617A1 (en) 2013-05-16
EP2776046A1 (en) 2014-09-17
JP2014532728A (ja) 2014-12-08
US20140336214A1 (en) 2014-11-13
CA2854512A1 (en) 2013-05-16
CN103906522B (zh) 2017-04-12
US9925182B2 (en) 2018-03-27
JP6593993B2 (ja) 2019-10-23
MX2014005571A (es) 2014-07-10
AU2012336030A1 (en) 2014-05-15
AU2012336030B2 (en) 2017-09-14
CN103906522A (zh) 2014-07-02
KR102016305B1 (ko) 2019-08-30
US9457024B2 (en) 2016-10-04
KR20140089577A (ko) 2014-07-15
US20170079975A1 (en) 2017-03-23
JP2018158940A (ja) 2018-10-11

Similar Documents

Publication Publication Date Title
MX348933B (es) Composiciones, formas de dosificacion y coadministracion de un compuesto agonista opioide y un compuesto analgesico.
MX354125B (es) Combinacion de un agonista opioide y un antagonista opioide en el tratamiento de la enfermedad de parkinson.
CR20130556A (es) FORMULACIÓN PARA ANTICUERPO ANTI-a4ß7
GT201400012A (es) Compuesto inhibidor de la señalizacion de la trayectoria notch
EA201301240A1 (ru) Полиморфная форма бензоата линаглиптина
ECSP12012318A (es) Inhibidores de pirazolil quinazolina cinasa
ECSP12012221A (es) Anticuerpos anti-cd40
DOP2014000031A (es) 4-(8-metoxi-1-((1-metoxipropan-2-il)-2-(tetrahidro-2h-piran-4-il)-1h-imidazo[4,5-c]quinolin-7-il)-3,5-dimetilisoxazol y su uso como inhibidor de bromodominio
EA201390804A1 (ru) Лекарственная форма лакозамида для приема один раз в сутки
GT201400261A (es) Solicitud pct face nacional novedosas n-piridinil amidas ciclicas sustituidas como inhibidores de quinasa
PL2714010T3 (pl) Kompozycja farmaceutyczna do miejscowego stosowania oparta na semifluorowanych alkanach
BR112013031493A2 (pt) composto, composição farmacêutica, uso de um composto, combinação de um composto, dispositivo e processo de preparação de um composto.
DOP2013000236A (es) Inhibidores de la poli(adp-ribosa)polimerasa(parp) para el tratamiento de la neuropatia periferica inducida por quimioterapia (cipn)
CL2015000289A1 (es) Compuesto citostatico derivado de niclosamida y compuesto alquilante derivado de 2,3,4,6,8-pentazabiciclo[4.3.0]nona-2,7-trieno; composicion farmaceutica que los comprende; y metodo para determinar si el tratamiento para un paciente con un tumor solido es adecuado.
BR112013028959A2 (pt) composto, processo para o preparo de um composto, combinação de um composto, composição farmacêutica, uso de um composto, dispositivo e kit
BR112014009950A2 (pt) composto dissubstituído, compostos e composição farmacêutica
CL2016002873A1 (es) Composición farmacéutica para reducir el daño talámico.
BR112014008555A2 (pt) r(+)-n-formil-propargil-aminoindano
BR112014002845A2 (pt) “composto, sal farmaceuticamente aceitável, composição farmacêutica, e, uso de um composto”
CO6920289A2 (es) Composición farmacéutica oftalmológica tópica que contiene regorafenib.
GB201105050D0 (en) Pharmaceutical agent
GT201400042A (es) Compuesto de benzotiazolona
BR112012020629A2 (pt) forma cristalina, e, método para a terapia de um distúrbio
BR112014009760A2 (pt) análogos de ácido siálico, seu uso e composição farmacêutica e composição farmacêutica de liberação sustentada os compreendendo
BR112013024196A2 (pt) complexos de gálio, composições farmacêuticas e métodos de uso

Legal Events

Date Code Title Description
FG Grant or registration